AG 1295 NEW
| Price | $47 | $80 | $146 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: AG 1295 | CAS No.: 71897-07-9 |
| Purity: 99.93% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | AG 1295 |
| Description | AG 1295, a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine-kinase, effectively halts PDGFR autophosphorylation without impacting the autophosphorylation of the EGF receptor[1][2][3][4]. |
| In vitro | AG1295 (10 μM, 100 μM) significantly inhibits rabbit conjunctival fibroblast cell growth stimulated by PDGF-AA or PDGF-BB in vitro[2]. AG 1295 inhibits PDGFR autophosphorylation with IC50s of 0.3-0.5 μM and 0.5-1 μM for membrane autophosphorylation assays and Swiss 3T3 cells, respectively[1]. |
| In vivo | AG-1295 reduces neointimal formation in aortic allograft vasculopathy by inhibiting PDGFR-beta-triggered tyrosine phosphorylation[3]. AG1295 (12 mg/kg; i.p.; daily; for 14 or 21 days) significantly decreases interstitial fibrosis, as evidenced by a smaller Sirius-Red stained area, fewer macrophages, reduced ED-A+ fibronectin deposition, and fewer alpha-smooth muscle actin-positive cells[4]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (256.08 mM), Sonication is recommended. |
| Keywords | RTK | Platelet-derived growth factor receptor | PDGF-receptor | PDGFR | Inhibitor | inhibit | autophosphorylation | AG-1295 | AG1295 | AG 1295 |
| Inhibitors Related | Regorafenib monohydrate | Sunitinib | Nintedanib | Imatinib Mesylate | Toceranib Phosphate | Sorafenib | Nintedanib esylate | Regorafenib | Lenvatinib mesylate | Lenvatinib | Pazopanib | Axitinib |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Cytokine Inhibitor Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Angiogenesis related Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3770.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-21 | |
|
VIP3Y
|
Chongqing Zhihe Biopharmaceutical Co., Ltd.
|
2026-06-29 | ||
| $5.00 |
VIP2Y
|
Hebei Jiafan Trading Company Limited
|
2026-06-30 | |
| $47.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
| $1.00 |
VIP8Y
|
Career Henan Chemical Co
|
2019-07-06 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY